{"id":2891,"date":"2025-10-30T11:30:19","date_gmt":"2025-10-30T11:30:19","guid":{"rendered":"https:\/\/network.rvrising.com\/?p=2891"},"modified":"2025-10-30T11:30:19","modified_gmt":"2025-10-30T11:30:19","slug":"intraoperative-radiation-therapy-market-to-double-by-2030-driven-by-precision-oncology-and-growing-cancer-incidence","status":"publish","type":"post","link":"https:\/\/www.rvrising.com\/news\/business\/intraoperative-radiation-therapy-market-to-double-by-2030-driven-by-precision-oncology-and-growing-cancer-incidence\/","title":{"rendered":"Intraoperative Radiation Therapy Market to Double by 2030 Driven by Precision Oncology and Growing Cancer Incidence"},"content":{"rendered":"<p><span class=\"legendSpanClass\">AUSTIN, Texas and TOKYO<\/span>, <span class=\"legendSpanClass\">Oct. 30, 2025<\/span> \/PRNewswire\/ &#8212; According to\u00a0<b>DataM Intelligence<\/b>, the <b>Intraoperative Radiation Therapy Market<\/b> is experiencing rapid technological and clinical adoption, underpinned by the surge in global cancer prevalence and a transition toward precision-based surgical oncology. The <b><a href=\"https:\/\/www.datamintelligence.com\/research-report\/intraoperative-radiation-therapy-market\" target=\"_blank\" rel=\"nofollow noopener\">IORT Market Size<\/a><\/b>\u00a0is estimated to be valued at around <b>USD 60 million in 2024<\/b> and is projected to reach <b>USD 120 million by 2030<\/b>, growing at a <b>CAGR of 6.6%<\/b>.<\/p>\n<div>\n<p>Rising cancer cases, estimated to exceed <b>27 million annually by 2040<\/b> (a 60% increase from 2018), are fueling the demand for innovative treatment modalities like IORT that reduce treatment cycles, improve patient recovery, and minimize exposure to healthy tissues.<\/p>\n<p><b>Recent Industry Developments (2024\u20132025)<\/b><\/p>\n<ul type=\"disc\">\n<li><b>Carl Zeiss AG<\/b>\u00a0expanded its IORT portfolio with new miniaturized applicators optimized for brain and GI cancer surgeries.<\/li>\n<li><b>Elekta AB<\/b>\u00a0entered a strategic partnership with <b>GMV<\/b> to enhance treatment planning software, integrating AI-based dose optimization.<\/li>\n<li><b>Ariane Medical Systems<\/b> reported a <b>22% increase in service revenue<\/b>, supported by its rapid maintenance network in Europe and Asia.<\/li>\n<li><b>Moffitt Cancer Center<\/b> initiated a multicenter trial in 2025 to evaluate 10-year survival outcomes of IORT vs. external beam radiotherapy in breast cancer patients.<\/li>\n<li><b>Japan&#8217;s National Cancer Center<\/b> began pilot testing portable IORT systems, aiming to reduce hospital treatment times by <b>up to 40%<\/b>.<\/li>\n<\/ul>\n<p><b>Download PDF Brochure: <\/b> <a href=\"https:\/\/www.datamintelligence.com\/download-sample\/intraoperative-radiation-therapy-market\" target=\"_blank\" rel=\"nofollow noopener\"> <b>https:\/\/www.datamintelligence.com\/download-sample\/intraoperative-radiation-therapy-market<\/b> <\/a><\/p>\n<p><b>Browse in-depth TOC on &#8220;Intraoperative Radiation Therapy Market&#8221;\u00a0<\/b><\/p>\n<p><b>76 \u2013 Tables<br class=\"dnr\" \/>69 \u2013 Figures<br class=\"dnr\" \/>194 \u2013 Pages<\/b><\/p>\n<p><b>Growth Drivers: Precision Oncology Meets Surgical Efficiency<\/b><\/p>\n<p>The adoption of IORT is accelerating due to its proven ability to deliver concentrated radiation doses directly to the tumor bed during surgery, thereby reducing recurrence and improving survival outcomes.<\/p>\n<p>Hospitals that implement IORT have reported up to <b>27% reduction in postoperative radiotherapy sessions<\/b> and <b>15\u201320% faster patient recovery rates<\/b> compared to traditional external beam radiotherapy. The technology also cuts hospital stay durations by an average of <b>1.5\u20132 days per patient<\/b>, resulting in significant cost efficiencies.<\/p>\n<p>DataM Intelligence estimates that over <b>1.9 million new cancer cases<\/b> were diagnosed in North America in 2024 alone, accounting for nearly <b>40% of IORT equipment sales globally<\/b>, highlighting the region&#8217;s early adoption of intraoperative modalities.<\/p>\n<p><b>Market Segmentation Analysis<\/b><\/p>\n<p><b>By Product and Service<\/b><\/p>\n<p>The IORT market includes <b>systems\/accelerators, applicators &amp; afterloaders, treatment planning systems, accessories<\/b>, and <b>services<\/b> such as installation, calibration, and training. The <b>product segment<\/b> accounts for approximately <b>75% of the market revenue<\/b>, with <b>systems and accelerators<\/b> leading at <b>over 40%<\/b> share in 2024. Service-related offerings are expected to grow at <b>7.5% CAGR<\/b>, driven by rising system installations and maintenance contracts across hospitals and clinics.<\/p>\n<p><b>By Technology<\/b><\/p>\n<p>The market is segmented into <b>Electron IORT (E-IORT)<\/b> and <b>Intraoperative Brachytherapy<\/b>. Electron IORT dominates with around <b>60% market share in 2024<\/b>, favored for its precision and reduced radiation leakage. Intraoperative brachytherapy, though smaller, is growing at <b>7.8% CAGR<\/b>, supported by adoption in specialized oncology centers and low-energy X-ray systems for superficial cancers.<\/p>\n<p><b>By Application<\/b><\/p>\n<p><b>Breast cancer<\/b>\u00a0represents the largest application area, accounting for <b>45.7%<\/b> of total IORT procedures in 2024, equating to approximately <b>USD 27 million<\/b> in revenue. Brain tumor and gastrointestinal cancer applications follow, together comprising <b>25%<\/b> of the global market. The breast cancer segment continues to expand at <b>6.9% CAGR<\/b>, supported by clinical validation and cost-effectiveness compared to prolonged external radiotherapy.<\/p>\n<p><b>By End-User<\/b><\/p>\n<p><b>Hospitals<\/b>\u00a0dominate the market, holding nearly <b>69% share<\/b> in 2024, as major tertiary centers integrate IORT systems into oncology surgery departments. <b>Ambulatory Surgical Centers (ASCs)<\/b> are the fastest-growing end-user segment with <b>8.7% CAGR<\/b>, reflecting the trend toward outpatient cancer treatments and the availability of compact mobile IORT units.<\/p>\n<p><b>Request for Customized Sample Report as per Your Business Requirement: <\/b> <a href=\"https:\/\/www.datamintelligence.com\/customize\/intraoperative-radiation-therapy-market\" target=\"_blank\" rel=\"nofollow noopener\"> <b>https:\/\/www.datamintelligence.com\/customize\/intraoperative-radiation-therapy-market<\/b> <\/a><\/p>\n<p><b>Regional Insights:<\/b><\/p>\n<p><b>United States<\/b><\/p>\n<p>The United States leads the global market with approximately <b>42% share in 2024<\/b>, translating to <b>USD 25 million<\/b> in revenue. This dominance stems from a dense oncology network, favorable reimbursement structures, and active clinical trials validating IORT&#8217;s long-term benefits. Over <b>160 hospitals and cancer centers<\/b> in the U.S. now operate IORT systems, a number expected to exceed <b>220 by 2028<\/b>.<\/p>\n<p>Recent trends show that <b>40% of new IORT installations<\/b> in North America are dedicated to breast and colorectal cancer, reflecting the shift toward targeted intraoperative radiation solutions.<\/p>\n<p><b>Japan<\/b><\/p>\n<p>Japan holds a modest but rapidly growing share, estimated at <b>USD 4.2 million in 2024<\/b> (around <b>7% of global revenue<\/b>). The Japanese market is expanding at a <b>CAGR of 7.2%<\/b>, fueled by government investments in radiation oncology infrastructure and clinical adoption in university hospitals. Recent government initiatives have allocated <b>over USD 20 million<\/b> to enhance localized cancer care technologies, including IORT.<\/p>\n<p><b>Competitive Landscape<\/b><\/p>\n<p>The IORT market is moderately consolidated, with leading manufacturers and research-driven centers driving innovation through collaborations and product advancements.<\/p>\n<p><b>Key Players:<\/b> <br class=\"dnr\" \/>Carl Zeiss AG, Ariane Medical Systems Ltd., Eckert &amp; Ziegler, Elekta AB, GMV, iCAD Inc., Moffitt Cancer Center, Xoft, Xinjiang Ke LAN Shuang Yi Medical Technology Stock Co., Ltd, E-Tech Industry Co., Ltd, and Derma Optic and Electronic Technique Co., Ltd.<\/p>\n<p><b>Market share and quantitative insights:<\/b><\/p>\n<ul type=\"disc\">\n<li><b>Carl Zeiss AG<\/b>\u00a0holds the largest share, accounting for nearly <b>30% of global IORT device installations<\/b>, with its INTRABEAM system adopted across <b>600+ hospitals worldwide<\/b>.<\/li>\n<li><b>Elekta AB<\/b>\u00a0and <b>Ariane Medical Systems<\/b> collectively hold <b>22% market share<\/b>, focusing on advanced accelerators and applicator systems.<\/li>\n<li><b>Xoft (a subsidiary of iCAD Inc.)<\/b> reported a <b>15% year-over-year increase in IORT system sales<\/b> in 2024, driven by rising use in early-stage breast cancer.<\/li>\n<li><b>Asian manufacturers<\/b>\u00a0such as <b>Xinjiang Ke LAN Shuang Yi Medical Technology<\/b> are expanding at over <b>10% CAGR<\/b>, supplying cost-effective accelerators for regional hospitals.<\/li>\n<\/ul>\n<p><b>Market Outlook and Opportunities<\/b><\/p>\n<p>According to DataM Intelligence, the IORT market will continue its upward trajectory through 2030, propelled by strong adoption in <b>breast and brain cancer surgeries<\/b>, continuous <b>R&amp;D investments<\/b>, and expansion of <b>ambulatory IORT centers<\/b>.<\/p>\n<p><b>Forecast highlights:<\/b><\/p>\n<ul type=\"disc\">\n<li>Electron IORT segment to exceed <b>USD 80 million by 2030<\/b>, driven by hospital procurement programs.<\/li>\n<li>Ambulatory surgical centers to contribute <b>USD 15 million by 2030<\/b>, reflecting decentralized oncology trends.<\/li>\n<li>Asia-Pacific region to record the <b>fastest CAGR of 7.8%<\/b>, supported by national cancer-control initiatives in Japan, China, and South Korea.<\/li>\n<\/ul>\n<p>With these developments, the global IORT industry is on course to transition from a specialized niche treatment to a standardized procedure within major oncology care frameworks.<\/p>\n<p><b>Conclusion<\/b><\/p>\n<p>The <b>Intraoperative Radiation Therapy (IORT) Market<\/b> is emerging as a transformative pillar of precision oncology, combining surgical accuracy with radiation efficacy. With an estimated growth from <b>USD 60 million in 2024<\/b> to <b>USD 120 million by 2030<\/b>, the market reflects a clear shift toward integrated cancer care.<\/p>\n<p>According to <b>DataM Intelligence<\/b>, the future of IORT will be shaped by technological miniaturization, service-based business models, and policy support for hospital-based radiotherapy innovation. As more healthcare systems embrace intraoperative radiotherapy, the next decade will see IORT evolve into a mainstream, patient-centric oncology solution worldwide.<\/p>\n<p><b>Buy This Exclusive Report at Just USD 4350 Only: <\/b> <a href=\"https:\/\/www.datamintelligence.com\/buy-now-page?report=intraoperative-radiation-therapy-market\" target=\"_blank\" rel=\"nofollow noopener\"> <b>https:\/\/www.datamintelligence.com\/buy-now-page?report=intraoperative-radiation-therapy-market<\/b> <\/a><\/p>\n<p><b>Related Report:<\/b><\/p>\n<ol type=\"1\">\n<li><a href=\"https:\/\/www.datamintelligence.com\/research-report\/radiation-therapy-equipment-market\" target=\"_blank\" rel=\"nofollow noopener\">Radiation Therapy Equipment Market Size<\/a>\u00a0Forecasted to Grow at ~6.2% CAGR Through 2031 as Cancer Treatment Technologies Surge.<\/li>\n<li><a href=\"https:\/\/www.datamintelligence.com\/research-report\/radiation-toxicity-treatment-market\" target=\"_blank\" rel=\"nofollow noopener\">Radiation Toxicity Treatment Market Size<\/a>\u00a0to Reach USD 4.6 B by 2030 with 6.1% CAGR, Driven by Rising Oncology Burden.<\/li>\n<\/ol>\n<p><b>About DataM Intelligence<\/b><\/p>\n<p>DataM Intelligence is a renowned provider of market research, delivering deep insights through pricing analysis, market share breakdowns, and competitive intelligence. The company specializes in strategic reports that guide businesses in high-growth sectors such as nutraceuticals and AI-driven health innovations.<\/p>\n<p>To find out more, visit <a href=\"https:\/\/www.datamintelligence.com\/\" target=\"_blank\" rel=\"nofollow noopener\">https:\/\/www.datamintelligence.com\/<\/a>\u00a0or follow us on <a href=\"https:\/\/x.com\/DataM_Research\" target=\"_blank\" rel=\"nofollow noopener\">Twitter<\/a>, <a href=\"https:\/\/www.linkedin.com\/company\/datam-intelligence\/\" target=\"_blank\" rel=\"nofollow noopener\">LinkedIn<\/a>\u00a0and <a href=\"https:\/\/www.facebook.com\/p\/DataM-Intelligence-4Market-Research-100076277393166\/\" target=\"_blank\" rel=\"nofollow noopener\">Facebook<\/a>.<\/p>\n<p><b>Contact:<\/b><\/p>\n<p>Sai Kiran<br class=\"dnr\" \/>DataM Intelligence 4market Research LLP<br class=\"dnr\" \/>Ground floor, DSL Abacus IT Park, Industrial Development Area<br class=\"dnr\" \/>Uppal, Hyderabad, Telangana 500039<br class=\"dnr\" \/><b>USA:<\/b>\u00a0+1 877-441-4866<br class=\"dnr\" \/><b>Email:<\/b>\u00a0<a href=\"http:\/\/www.prnewswire.com\/cdn-cgi\/l\/email-protection#0457656d2a6f4460657065696d6a706168686d63616a67612a676b69\" target=\"_blank\" rel=\"nofollow noopener\"><span class=\"__cf_email__\" data-cfemail=\"3d6e5c5413567d595c495c50545349585151545a58535e58135e5250\">[email\u00a0protected]<\/span><\/a><\/p>\n<p>Logo: <a href=\"https:\/\/mma.prnewswire.com\/media\/1858619\/3573087\/DataM_Intelligence_Logo.jpg\" target=\"_blank\" rel=\"nofollow noopener\">https:\/\/mma.prnewswire.com\/media\/1858619\/3573087\/DataM_Intelligence_Logo.jpg<\/a><\/p>\n<p>SOURCE DataM Intelligence 4 Market Research LLP<\/p>\n<\/div>\n<p><b>This release is auto-published via PR Newswire; our journal is not responsible for the content.<\/b><\/p>\n<p><a href=\"https:\/\/www.prnewswire.com\/news-releases\/intraoperative-radiation-therapy-market-to-double-by-2030-driven-by-precision-oncology-and-growing-cancer-incidence--datam-intelligence-302599719.html\">Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>AUSTIN, Texas and TOKYO, Oct. 30, 2025 \/PRNewswire\/ &#8212; According to\u00a0DataM Intelligence, the Intraoperative Radiation Therapy Market is<\/p>\n","protected":false},"author":1,"featured_media":2892,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[8,92],"tags":[508],"class_list":["post-2891","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business","category-pr-newswire","tag-datam-intelligence-4-market-research-llp"],"_links":{"self":[{"href":"https:\/\/www.rvrising.com\/news\/wp-json\/wp\/v2\/posts\/2891","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.rvrising.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.rvrising.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.rvrising.com\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.rvrising.com\/news\/wp-json\/wp\/v2\/comments?post=2891"}],"version-history":[{"count":1,"href":"https:\/\/www.rvrising.com\/news\/wp-json\/wp\/v2\/posts\/2891\/revisions"}],"predecessor-version":[{"id":2899,"href":"https:\/\/www.rvrising.com\/news\/wp-json\/wp\/v2\/posts\/2891\/revisions\/2899"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.rvrising.com\/news\/wp-json\/wp\/v2\/media\/2892"}],"wp:attachment":[{"href":"https:\/\/www.rvrising.com\/news\/wp-json\/wp\/v2\/media?parent=2891"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.rvrising.com\/news\/wp-json\/wp\/v2\/categories?post=2891"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.rvrising.com\/news\/wp-json\/wp\/v2\/tags?post=2891"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}